| Bioactivity | Hydromethylthionine dihydrobromide (Leukomethylene blue dihydrobromide; LMTM dihydrobromide) is a potent inhibitor of TAU protein aggregation. Hydromethylthionine dihydrobromide reduces neurodegeneration by interacting with TAU proteins and preventing them from forming neurotoxic aggregates. Hydromethylthionine dihydrobromide can be used in the study of Alzheimer's disease and other TAU related disorders[1]. |
| CAS | 951131-15-0 |
| Formula | C16H21Br2N3S |
| Molar Mass | 447.23 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kondak C, et al. Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine[J]. Journal of neurochemistry, 2022, 160(2): 172-184. |
Hydromethylthionine dihydrobromide
CAS: 951131-15-0 F: C16H21Br2N3S W: 447.23
Hydromethylthionine dihydrobromide (Leukomethylene blue dihydrobromide; LMTM dihydrobromide) is a potent inhibitor of TA
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.